Atlas Trials

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Clinical trial NCT06407310 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06407310
Sponsor
Tel Aviv Medical Center
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2024-07-01
Primary completion
2027-04-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.